Clinical Trial

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Study acronym: TRAVELLER
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Protocol Amendment History 2 changes
notable Enrollment increased: 13000 -> 80000 participants 2026-07-25
notable Trial sites expanded: 207 -> 211 locations 2026-04-07
Trial Details
NCT Number NCT07177352
Lead Sponsor Hoffmann-La Roche
Conditions Alzheimers Disease
Enrollment 80,000 participants
Start Date 2025-07-02
Primary Completion 2035-07-31 (estimated)
Study Completion 2035-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-24